NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 15.
PROPERTY, PLANT AND EQUIPMENT Continued The net book value of the Groups property, plant and equipment includes an amount of $17,151,000 2011: $18,229,000 in respect of assets held under finance lease.
As at 31 December 2012, the Group had pledged property, plant and equipment having a carrying value of $135,166,000 2011: $150,268,000 as collateral for various long-term loans.
This amount includes both specic items around the Group and the net property, plant and equipment of the Groups businesses in Portugal, Egypt, US, Germany and Tunisia 2011: Portugal, Egypt, Saudi Arabia, US, and Tunisia.
In 2008, the German Government provided Thymoorgan Pharmazie GmbH with a grant of Euro 560,000, being a contribution towards the purchase of two freeze dryers and additional equipment.
During the year 2012, the Group entered into contractual commitments for the acquisition of property, plant and equipment amounting to $2,800,000 2011: $166,000.
The amount of borrowing costs that have been capitalised in the year, within the projects under construction, is $68,000 2011: $781,000.
The average capitalisation rate used ranges between 2.87%11.00% 2011: 3.12%10.50%.
INTEREST IN ASSOCIATED COMPANIES On 15 April 2011, the Group acquired a non-controlling interest of 23.1% in the Indian company Unimark Remedies Limited Unimark through the subscription of new equity for a cash consideration of $33,609,000.
Through this strategic partnership, Hikma and Unimark will collaborate on the development of strategic APIs and new product formulations.
Unimarks strong technical and R&D capabilities will complement Hikmas in-house R&D efforts and are expected to enable Hikma to bring more products in more therapeutic categories to market globally.
On 28 June 2011, the Group acquired a non-controlling interest of 30.1% in Hubei Haosun Pharmaceutical Co. Ltd Haosun through the subscription of new equity, for a cash consideration of $5,000,000.
Through this partnership Hikma gains access to a high quality, long-term source of API, particularly in the strategically important area of oncology.
Gains of $892,000, representing the Groups share of the results of associates, are included in the consolidated income statement.
For the For the year ended year ended 31 December 31 December 2012 2011 $000 $000 Balance at 1 January 2012 37,445 Additions 38,609 Share of income loss of associates 892 1,164 Balance at 31 December 38,337 37,445 Summarised financial information in respect of the Groups interests in associated companies is set out below: For the For the year ended year ended 31December 31 December 2012 2011 $000 $000 Total assets 227,345 192,645 Total liabilities 118,640 93,424 Net assets 108,705 99,221 Groups share of net assets of associates 25,947 23,775 Total revenues 139,596 89,659 Net income loss 3,974 6,017 Groups share of income loss of associates 892 1,164 The information above is adjusted for fair value adjustments arising on acquisition and to comply with the Groups accounting policies.
138 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
